Novartis is getting its third oncology chief in less than a year after Liz Barrett said on Thursday she was leaving the Swiss drugmaker to become chief executive of a U.S. biotech firm only 11 months after taking up the role.
Barrett, a U.S. citizen who previously worked at Pfizer and Johnson & Johnson J&J.N before joining Novartis in February, will be replaced from January by Susanne Schaffert, a longtime Novartis executive.
Barrett, who could not be reached for comment, cited challenges in moving her family to Basel, Novartis’s headquarters, as the reason for her departure. She did not name the biotechnology firm she was joining.
Novartis is trying to build up its oncology portfolio with new therapies including its costly Kymriah cell therapy, nuclear-based medicines and immuno-oncology.
“After much personal reflection, it became clear that my family would be unable to relocate,” said Barrett, who had replaced Bruno Strigini as oncology chief less than a year ago.
A Novartis spokesman said he did not know where Barrett had taken a job.
Schaffert, a 20-year Novartis veteran, had for five years been Region Head, Novartis Oncology Europe, before this year taking over at its Advanced Accelerator Applications (AAA) unit, purchased late last year for $3.9 billion.
AAA makes therapies that deploy trace amounts of radioactive compounds to treat cancer.
Schaffert will replace Barrett on the Novartis executive committee, where she will report to Chief Executive Vas Narasimhan.
“She has our full support and confidence as we continue to invest in both our internal pipeline as well as external assets to strengthen our presence,” Narasimhan said in a statement.
By Silke Koltrowitz and John Miller
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).